Multifocal Motor Neuropathy (MMN)

🧠 Standard of Care & Symptoms

Multifocal Motor Neuropathy (MMN) is a rare, slowly progressive, immune-mediated peripheral neuropathy characterized by asymmetric muscle weakness without sensory loss. Correct diagnosis is critical, as it can mimic motor neuron diseases like ALS but is highly treatable.

• Presentation: Key features.
  • *Asymmetric Weakness:* Typically begins distally in the upper limbs, affecting the hands and arms (causing difficulty with writing, key turning, or wrist/finger drop).
  • *No Sensory Deficits:* Numbness, tingling, or sensory loss is absent, which distinguishes MMN from other neuropathies.
  • *Fasciculations & Cramps:* Twitching (fasciculations) and severe muscle cramps are common in the weak limbs, often leading to initial misdiagnosis as ALS.
  • *Hyporeflexia:* Reflexes are typically decreased or absent in the affected limbs, but remain normal in clinically unaffected muscles.

🧬 Diagnostics & Conduction Block Pathophysiology

Diagnosis requires detailed electrodiagnostic studies to identify motor conduction blocks while verifying normal sensory nerve function.

• Diagnostic Markers: Key criteria.
  • Nerve Conduction Studies (NCS): Demonstrates persistent, multifocal **motor conduction blocks** (CB) along motor axons outside common entrapment sites (e.g. not at the carpal tunnel). Sensory nerve conduction studies over the same segments must be completely normal.
  • Anti-GM1 Antibody Titers: High serum titers of **anti-GM1 IgM autoantibodies** are detected in 50% to 80% of patients.
  • Cerebrospinal Fluid (CSF) Analysis: CSF protein levels are typically normal or only slightly elevated, helping rule out Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Pathophysiology of Focal Demyelination

The motor deficit in MMN results from targeted antibody attack on myelin components:

• Anti-GM1 IgM Autoantibodies: Antibodies target **GM1 gangliosides**, which are glycolipids highly enriched at the **Nodes of Ranvier** and myelin sheath of motor nerves.
• Complement-Mediated Injury: Binding of IgM to GM1 recruits and activates the complement cascade. This results in local node disruption and focal demyelination along the axon.
• Conduction Block: Demyelination prevents saltatory conduction of electrical signals. Action potentials are blocked at the site of the lesion, leading to muscle weakness, while the axon distal to the block remains viable for long periods.

💊 Immunoglobulin & Biologic Support

MMN is highly responsive to immunomodulatory therapy. First-line treatment centers on high-dose immunoglobulins, while steroids are avoided.

First-Line Immunoglobulin Therapy

• Intravenous Immunoglobulin (IVIG): The gold standard. High-dose IVIG (2.0 g/kg over 2-5 days) leads to rapid improvement in muscle strength within days in up to 80% of patients. Because MMN is progressive, periodic maintenance infusions (every 2 to 6 weeks) are required.
• Subcutaneous Immunoglobulin (SCIG): Used for maintenance therapy, allowing self-administration at home and providing stable serum IgG levels.

Contraindications & Targeted Agents

• Steroid Avoidance: Corticosteroids (e.g. Prednisone) and plasma exchange (plasmapheresis) are generally ineffective in MMN and can paradoxically worsen muscle weakness.
• Complement Blockers: Biologic therapies targeting the complement cascade (e.g. terminal complement C5 inhibitors like **Ravulizumab**) are under evaluation as steroid-free maintenance adjuncts to reduce IVIG dosing frequency.

🔬 Active Clinical Trials

Clinical trials are currently evaluating terminal complement inhibitors, subcutaneous maintenance algorithms, and advanced electrodiagnostic tracking.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Multifocal Motor Neuropathy, establish these clinical care pathways:

1. Establish IVIG Treatment: Consult with a neuromuscular neurologist to schedule your initial high-dose IVIG loading protocol.
2. Confirm GM1 Status: Complete anti-GM1 antibody testing to support your clinical profile for insurance and trial eligibility.
3. Avoid Steroid Prescriptions: Ensure your care team is aware that corticosteroids should be avoided as they can exacerbate weakness.
4. Engage with Occupational Therapy: Work with an occupational therapist for custom hand braces or tools to support fine motor tasks.

❓ Patient FAQ

Q: Is MMN the same as ALS?
A: No. MMN and ALS (Lou Gehrig's disease) can share symptoms like asymmetric hand weakness, cramps, and twitches. However, ALS is a fatal disease affecting both upper and lower motor neurons with no cure. MMN is an autoimmune disorder affecting only peripheral motor nerves, does not affect life expectancy, and is highly treatable with IVIG.

Q: How often do I need IVIG infusions?
A: IVIG does not cure MMN but temporarily restores conduction across the block. Most patients require maintenance infusions every 2 to 6 weeks. If infusions are delayed, weakness typically returns.